AdaptHealth (NASDAQ:AHCO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.
A number of other analysts have also weighed in on the stock. UBS Group cut their price objective on shares of AdaptHealth from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday. Weiss Ratings restated a "sell (d)" rating on shares of AdaptHealth in a research report on Friday, May 22nd. Truist Financial lowered their price target on shares of AdaptHealth from $14.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday. Robert W. Baird set a $10.00 price target on AdaptHealth in a research report on Wednesday. Finally, Jefferies Financial Group upgraded AdaptHealth from a "hold" rating to a "buy" rating and lifted their price objective for the company from $11.00 to $13.00 in a research note on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $10.29.
View Our Latest Research Report on AHCO
AdaptHealth Stock Performance
AHCO opened at $5.69 on Friday. AdaptHealth has a 12-month low of $5.66 and a 12-month high of $13.43. The company has a current ratio of 1.12, a quick ratio of 0.71 and a debt-to-equity ratio of 1.37. The firm has a market capitalization of $773.33 million, a PE ratio of -3.33, a P/E/G ratio of 0.31 and a beta of 1.47. The firm has a 50 day moving average of $9.96 and a two-hundred day moving average of $10.55.
Insider Buying and Selling at AdaptHealth
In other AdaptHealth news, insider Russell E. Schuster III sold 11,275 shares of the company's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $10.06, for a total value of $113,426.50. Following the completion of the transaction, the insider owned 136,538 shares in the company, valued at approximately $1,373,572.28. This represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.95% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On AdaptHealth
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB purchased a new stake in AdaptHealth during the 2nd quarter valued at about $226,000. Empowered Funds LLC raised its holdings in AdaptHealth by 1.4% in the 1st quarter. Empowered Funds LLC now owns 622,904 shares of the company's stock valued at $7,413,000 after acquiring an additional 8,602 shares during the last quarter. Quantinno Capital Management LP lifted its stake in AdaptHealth by 140.0% in the 1st quarter. Quantinno Capital Management LP now owns 109,694 shares of the company's stock worth $1,305,000 after purchasing an additional 63,992 shares in the last quarter. Lazard Asset Management LLC lifted its stake in AdaptHealth by 35.0% in the 1st quarter. Lazard Asset Management LLC now owns 1,669,454 shares of the company's stock worth $19,867,000 after purchasing an additional 432,664 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of AdaptHealth by 10.1% during the 1st quarter. Renaissance Technologies LLC now owns 228,373 shares of the company's stock worth $2,718,000 after purchasing an additional 21,000 shares during the last quarter. Institutional investors and hedge funds own 82.67% of the company's stock.
AdaptHealth Company Profile
(
Get Free Report)
AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.
The company's respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider AdaptHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AdaptHealth wasn't on the list.
While AdaptHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
